High Performance - Yellow Chalkboard with Hand Drawn Text and White Cup of Coffee on Wooden Table. Top View..jpeg

Happy Holidays! Thanks to all of our readers for a great 2016. Below is a top 10 countdown of Advera Health's most read blog posts of the year with links to the full post. Enjoy.


#1 The Comparative Safety of Multiple Sclerosis Medications – A 2016 Update

Back in June of 2014, the Advera Health team (under our old AdverseEvents banner) wrote our most downloaded report of all time, comparing the safety of MS medications. Given its popularity, I believe that covering the clinical evidence side of MS, including analysis of the drugs’ efficacy, will fill a much needed evidence gap for Evidex subscribers. Read More


#2 It’s Confirmed: FDA is Failing When it Comes to Drug Safety

Recently a report by the U.S. Government Accountability Office (GAO), filed at the request of Representative Rosa DeLauro on December 15, 2015 was made public. The report’s focus was to better understand the rate at which drug applications were expedited using “fast track” and “breakthrough therapy” designations and if FDA was fulfilling its duty to properly track and analyze post-marketing monitoring for those drugs.

The answer was no. The FDA is not fulfilling its duty to the American public in regards to drug safety. Read More


#3 Why Does Adverse Event Reporting to FAERS Continue to Accelerate?

Seventy two hours after 2016 Q2 FDA Adverse Event Reporting System (FAERS) data were publicly released by FDA, our RxFilter® process had it standardized and loaded into the Evidex platform.  Based on the volume of data in Q2, it looks like we’re well on the way to yet another record year of adverse events reported into FAERS. Read More


#4 Watson Health is the Ultimate Data Parasite

One year after its birth, the ultimate data parasite has come of age by latching on to a $3 billion host. It is big, blue, pretty good at Jeopardy, and if you were to believe the data detractors, utterly useless. Read More

#5 Express Scripts’ 2017 Exclusions – Analysis Using Real World Data

It has become tradition at Advera Health to look closely at the annual formulary exclusions that the large payers such as Express Scripts introduce every August. Using our safety scoring and costing algorithms we are able to quickly provide a top-line view into the effects of their decisions. Read More


#6 Chronic Underreporting of Clinical Trials

We wrote about STAT’s original investigative work back in December and I’d urge you to read their report (link is above) and our blog post published shortly thereafter.  For those short on time, here’s the skinny:  top research institutions that rely most heavily on NIH funding are oftentimes the ones most delinquent in making the legally required reporting of study results.  This violates the terms of their funding and federal law. Read More

#7 Safety Score & Cost Burden Analysis Update – Which Drugs have Riskiest Profiles?

In June, the Advera analyst team combed through prescription and patient population data supplied by our partners at Evaluate Pharma to update our RxScore and RxCost analytics site-wide. The end result yielded 53 drugs with first-time RxScores and 69 drugs with first-time RxCosts. Read More


#8 How Will You Review All 60 drugs up for Approval in 2016?

It was a big week for us here at Advera Health. On Tuesday we released Evidex™, the next generation of our drug informatics platform that combines annotated data from curated clinical trial results together with structured real world evidence. We are extremely excited about Evidex, as it provides the first end-to-end solution that greatly increases the speed and efficiency of drug reviews by our clients. Read More


#9 Drug Safety Snail Mail. Really?

Last week the U.S. Surgeon General Vivek Murthy sent a letter to every doctor in the U.S. to warn them of the dangers of opioid addiction.  While certainly well intentioned, I have to ask - in this age of technology, is this the best we can do?  Why not fax or, even better, send a Western Union cable? Read More


#10 Evidex Use Case: Analysis of DPP-4 Inhibitors

Last week we officially launched our revamped platform Evidex, which now includes easy-to-navigate evidence from both clinical trial data and real-world adverse event reports. To give you an idea of how simple it is to complete a thorough drug review in this platform, I'll go through a step-by-step overview of how to compare multiple diabetes meds. Read More


Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.